Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Daniel Rooks, R. Roubenoff
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Ageing populations: the 1. Cruz-Jentoft AJ, Landi F, Schneider SM, et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS)
10.1093/ageing/afu115 · 2014
The healthcare costs of sarcopenia in the United States
10.1111/j.1532-5415.2004.52014.x · 2004
Sarcopenia
10.1016/j.berh.2017.11.007 · 2017
Aging of skeletal muscle: a 12-yr longitudinal study
10.1152/jappl.2000.88.4.1321 · 2000
Innervation and neuromuscular control in ageing skeletal muscle
10.1113/jp270561 · 2016
Sarcopenia: burden and challenges for public health
10.1186/2049-3258-72-45 · 2014
Fighting the inevitability of ageing
10.1038/d41586-018-02479-z · 2018
Unresolved referenced work
2017
Unresolved referenced work
2018
Exercise and physical activity for older adults
10.1249/mss.0b013e3181a0c95c · 2009
Highintensity strength training in nonagenarians. Effects on skeletal muscle
10.1001/jama.1990.03440220053029 · 1990
Strength conditioning in older men: skeletal muscle hypertrophy and improved function
10.1152/jappl.1988.64.3.1038 · 1988
Effectiveness of exercise interventions on physical function in community-dwelling frail older people: an umbrella review of systematic reviews
10.11124/jbisrir-2017-003551 · 2018
Effect of structured physical activity on prevention of major mobility disability in older adults: the LIFE study randomized clinical trial
10.1001/jama.2014.5616 · 2014
Dose of physical activity, physical functioning and disability risk in mobility-limited older adults: Results from the LIFE study randomized trial
10.1371/journal.pone.0182155 · 2017
Effects of resistance training, endurance training and whole-body vibration on lean body mass, muscle strength and physical performance in older people: a systematic review and network metaanalysis
10.1093/ageing/afy009 · 2018
Progressive resistance strength training for improving physical function in older adults
2009
Unresolved referenced work
2013
Protein requirements and recommendations for older people: A review
10.3390/nu7085311 · 2015
Nutritional intervention in sarcopenia: Report from the International Conference on Frailty and Sarcopenia Research Task Force
2018
Physical inactivity among older adults across Europe based on the SHARE database
10.1093/ageing/afw165 · 2017
Cross-sectional and longitudinal factors influencing physical activity of 65 to 75-year-olds: a pan European cohort study based on the survey of health, ageing and retirement in Europe (SHARE)
10.1186/s12877-018-0781-8 · 2018
Unresolved referenced work
2017
Adherence to physical exercise recommendations in people over 65—the SNAC-Kungsholmen study
10.1093/eurpub/cks150 · 2013
Effects of exercise and aging on skeletal muscle
10.1101/cshperspect.a029785 · 2018
Effects of protein supplementation combined with resistance exercise on body composition and physical function in older adults: a systematic review and meta-analysis
10.3945/ajcn.116.143594 · 2017
Does nutrition play a role in the prevention and management of sarcopenia
10.1016/j.clnu.2017.08.016 · 2018
Physical frailty and sarcopenia (PF&S): a point of view from the industry
10.1007/s40520-016-0710-7 · 2017
Signaling pathways controlling skeletal muscle mass
10.3109/10409238.2013.857291 · 2014
Myostatin/activin pathway antagonism: Molecular basis and therapeutic potential
10.1016/j.biocel.2013.05.019 · 2013
Sarcopenia: origins and clinical relevance
10.1093/jn/127.5.990s · 1997
Sarcopenia: European consensus on definition and diagnosis Report of the European Working Group on Sarcopenia in Older People
10.1093/ageing/afq034 · 2010
Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”
10.1016/j.clnu.2009.12.004 · 2010
Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia
10.1016/j.jamda.2011.01.003 · 2011
Sarcopenia in Asia: Consensus report of the Asian working group for sarcopenia
2014
The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates
10.1093/gerona/glu010 · 2014
Sarcopenia: revised European consensus on definition and diagnosis
10.1093/ageing/afy169 · 2019
Sarcopenia is associated with incident disability, institutionalization, and mortality in community-dwelling older men: The Concord Health and Ageing in Men project
10.1016/j.jamda.2015.02.006 · 2015
Prevalence of sarcopenia in community-dwelling Chilean elders according to an adapted version of the European Working Group on Sarcopenia in Older People (EWGSOP) criteria
2017
The prevalence of sarcopenia in very old individuals according to the European consensus definition: insights from the BELFRAIL study
10.1093/ageing/aft128 · 2013
CK-2127107 amplifies skeletal muscle response to nerve activation in humans
10.1002/mus.26017 · doi-reference
Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes
10.1111/cen.13601 · doi-reference
Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals
10.1111/dom.13042 · doi-reference
Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer
10.1210/jc.2014-1271 · doi-reference
A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy
10.1002/ana.21338 · doi-reference
Locally acting ACE-083 increases muscle volume in healthy volunteers
10.1002/mus.26113 · doi-reference
ACE-083, a locally-acting TGF-ß; superfamily ligand trap, increases muscle mass and strength in a mouse model of Duchenne muscular dystrophy
10.1016/j.nmd.2016.06.160 · doi-reference
Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial
10.1002/mus.25268 · doi-reference
A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers
10.1002/mus.23539 · doi-reference
Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type
10.1152/japplphysiol.00866.2009 · doi-reference
Treatment of sarcopenia with bimagrumab: Results from a phase II, randomized, controlled, proof-of-concept study
10.1111/jgs.14927 · doi-reference
Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy
10.1002/jcsm.12205 · doi-reference
10.1186/s13395-017-0141-y
10.1186/s13395-017-0141-y · doi-reference
Myostatin neutralization results in preservation of muscle mass and strength in preclinical models of tumor-induced muscle wasting
10.1158/1535-7163.mct-14-0681 · doi-reference
Activin A more prominently regulates muscle mass in primates than does GDF8
10.1038/ncomms15153 · doi-reference
Safety, tolerability, pharmacokinetics, and pharmacodynamics of domagrozumab (PF-06252616), an anti-myostatin monoclonal antibody in healthy subjects
10.1002/cpdd.386 · doi-reference
Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial
10.1016/s2213-8587(15)00298-3 · doi-reference
Myostatin mutation associated with gross muscle hypertrophy in a child
10.1056/nejmoa040933 · doi-reference
Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy
10.1073/pnas.1707925114 · doi-reference
An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy
10.1128/mcb.01307-13 · doi-reference
Regulation of muscle growth by multiple ligands signaling through activin type II receptors
10.1073/pnas.0505996102 · doi-reference
GDF11 increases with age and inhibits skeletal muscle regeneration
10.1016/j.cmet.2015.05.010 · doi-reference
TAK-1/p38/nNF?B signaling inhibits myoblast differentiation by increasing levels of Activin A
10.1186/2044-5040-2-3 · doi-reference
Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size
10.1152/ajpcell.00105.2009 · doi-reference
Regulation of skeletal muscle maßs in mice by a new TGF-ß superfamily member
10.1038/387083a0 · doi-reference
The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebocontrolled phase II trial
10.1007/s13539-011-0034-6 · doi-reference
A phase IIA randomized, placebocontrolled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia
10.1007/s12603-013-0335-x · doi-reference
Effects of a novel selective androgen receptor modulator on dexamethasone-induced and hypogonadism-induced muscle atrophy
10.1210/en.2010-0150 · doi-reference
Development of selective androgen receptor modulators (SARMs)
10.1016/j.mce.2017.06.013 · doi-reference
Pharmacologic options for the treatment of sarcopenia
10.1007/s00223-015-0022-5 · doi-reference
Oral drugs related with muscle wasting and sarcopenia. A review
10.1159/000448247 · doi-reference
Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia
10.1007/s40520-015-0517-y · doi-reference
Designing, implementing, and evaluating mobile health technologies for managing chronic conditions in older adults: A scoping review
10.2196/mhealth.5127 · doi-reference
Digital health revolution: perfect storm or perfect opportunity for pharmaceutical R&D
10.1016/j.drudis.2016.01.010 · doi-reference
Muscle weakness and physical disability in older Americans: Longitudinal findings from the U.S. Health and Retirement Study
10.1007/s12603-017-0951-y · doi-reference
The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study
10.1093/gerona/61.10.1059 · doi-reference
The nonlinear relationship between gait speed and falls: the Maintenance of Balance, Independent Living, Intellect, and Zest in the Elderly of Boston Study
10.1111/j.1532-5415.2011.03408.x · doi-reference
Walking pace and the risk of cognitive decline and dementia in elderly populations: A meta-analysis of prospective cohort studies
10.1093/gerona/glw121 · doi-reference
Gait speed and survival in older adults
10.1001/jama.2010.1923 · doi-reference
Role of gait speed in the assessment of older patients
10.1001/jama.2010.1970 · doi-reference